Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thompson test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Thompson test. Displaying page 1 of 1.
    EudraCT Number: 2006-000576-33 Sponsor Protocol Number: RBN 542 Start Date*: 2006-06-13
    Sponsor Name:St Helens & Knowsley Hospitals NHS Trust [...]
    1. St Helens & Knowsley Hospitals NHS Trust
    2. Universtiy of Liverpool
    Full Title: Pilot Study to investigate the role of Glutamine in the early protective stress response
    Medical condition: Critical Illness
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003063-12 Sponsor Protocol Number: NEU-01-02-1A Start Date*: 2016-09-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: TIBC study: A multiple-centre Phase 2 trial comparing the efficacy of 2-Iminobiotin (2-IB) treatment to standard care in neonates with gestational age of ≥36 weeks with moderate to severe perinatal...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    19.0 100000004868 10028946 Neonatal hypoxia and asphyxia HLT
    19.0 100000004852 10021147 Hypoxic encephalopathy LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10022820 Intrauterine hypoxia and birth asphyxia LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10040441 Severe birth asphyxia LLT
    19.0 100000004852 10070512 Hypoxic-ischemic encephalopathy LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-014344-11 Sponsor Protocol Number: prot-001-2009 Start Date*: 2010-06-02
    Sponsor Name:Imperial College London
    Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial
    Medical condition: Neonatal asphyxial encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    12 10028946 neonatal hypoxia and asphyxia SOC
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003435-40 Sponsor Protocol Number: CTU 0095 Start Date*: 2006-08-29
    Sponsor Name:Department of Health
    Full Title: A Randomised Controlled Trial to Investigate the effectiveness of the Healthy Sexual Functioning (HSF) Module and Selective Serotonin Reuptake Inhibitor (SSRI) Medication to treat Deviant Sexual Ar...
    Medical condition: Deviant Sexual Arousal (sex offender)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063494 Sexual offence LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004980-36 Sponsor Protocol Number: MS200527-0082 Start Date*: 2020-09-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) LT (Completed) SK (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Prematurely Ended) NO (Prematurely Ended) ES (Completed) DE (Prematurely Ended) SI (Completed) IT (Prematurely Ended) RO (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001511-73 Sponsor Protocol Number: WA40404 Start Date*: 2019-12-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition:
    Disease:
    Population Age: Gender:
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002145-11 Sponsor Protocol Number: 101MS329 Start Date*: 2019-03-21
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Rela...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004972-20 Sponsor Protocol Number: MS200527ˍ0080 Start Date*: 2020-11-05
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) HU (Prematurely Ended) BE (Completed) CZ (Completed) BG (Completed) ES (Completed) FI (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001138-10 Sponsor Protocol Number: F-FR-00250-105 Start Date*: 2016-01-06
    Sponsor Name:Ipsen Pharma SAS
    Full Title: Efficacy of diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults. A multicentre, randomised, double-blind, placebo-controlled, parallel groups study
    Medical condition: Acute diarrhoea in adult
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10055955 Acute diarrhoea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-001205-23 Sponsor Protocol Number: OVERLORD-MS Start Date*: 2020-07-10
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
    Medical condition: Remitting Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001600-38 Sponsor Protocol Number: 27018966IBS3001 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004009-15 Sponsor Protocol Number: VIS410-203 Start Date*: 2017-07-03
    Sponsor Name:Visterra, Inc.
    Full Title: Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in ...
    Medical condition: Influenza A infection in hospitalized patients who need supplemental oxygen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) EE (Completed) LV (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001601-24 Sponsor Protocol Number: 27018966IBS3002 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    14.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002531-32 Sponsor Protocol Number: GWCL0405 Start Date*: 2005-07-28
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia
    Medical condition: Peripheral neuropathic pain associated with allodynia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005677-23 Sponsor Protocol Number: CFTY720D2311 Start Date*: 2013-04-02
    Sponsor Name:Novartis Farma
    Full Title: A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) LT (Completed) SK (Trial now transitioned) LV (Ongoing) ES (Ongoing) DE (Trial now transitioned) BG (Completed) PL (Completed) AT (Completed) NL (Completed) SE (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned) EE (Completed) FR (Trial now transitioned) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-005038-39 Sponsor Protocol Number: Start Date*: 2020-12-02
    Sponsor Name:Queen Mary University of London
    Full Title: ChariotMS – A national (UK), multi-centre, randomised, double-blind, placebo-controlled (1:1) phase IIb efficacy trial with cost-utility analysis of cladribine tablets (3.5mg/kg over two years) in ...
    Medical condition: Advanced Multiple Sclerosis (EDSS 6.5-8.5)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10052785 Multiple sclerosis acute and progressive HLT
    20.1 10029205 - Nervous system disorders 10078558 Multiple sclerosis plaque LLT
    22.1 10029205 - Nervous system disorders 10028246 Multiple sclerosis aggravated LLT
    20.1 10028245 - Multiple sclerosis 10078559 Multiple sclerosis brain lesion LLT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10064137 Progression of multiple sclerosis LLT
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002672-13 Sponsor Protocol Number: RH/BARACKD/0003 Start Date*: 2013-04-09
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance Office
    Full Title: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial: a prospective randomised open blinded endpoint trial to determine the effect of aldosterone receptor antagoni...
    Medical condition: We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate marke...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    15.1 10022891 - Investigations 10018355 Glomerular filtration rate PT
    15.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002560-41 Sponsor Protocol Number: 0611 Start Date*: 2017-09-21
    Sponsor Name:University of Leicester
    Full Title: A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker Regimen to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): A Feasibility Trial
    Medical condition: Participants in the trial will have had a transient ischaemic attack (TIA) or an acute ischaemic stroke and will also have hypertension. The trial will investigate the possible treatment of blood p...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10060840 Ischaemic cerebral infarction PT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    20.0 10047065 - Vascular disorders 10020783 Hypertension not adequately controlled LLT
    20.0 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    20.0 10047065 - Vascular disorders 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003227-38 Sponsor Protocol Number: EMR700623_535 Start Date*: 2013-03-07
    Sponsor Name:Merck Serono
    Full Title: A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects with Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing ...
    Medical condition: Anovulation in women with PCOS
    Disease: Version SOC Term Classification Code Term Level
    16.1 10042613 - Surgical and medical procedures 10033312 Ovulation induction PT
    16.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000894-26 Sponsor Protocol Number: BN42083 Start Date*: 2020-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL...
    Medical condition: Primary Progressive Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:23:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA